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Abstract: Consuming fermented foods has been reported to result in improvements in a range of
health parameters. These positive effects can be exerted by a combination of the live microorganisms
that the fermented foods contain, as well as the bioactive components released into the foods as
by-products of the fermentation process. In many instances, and particularly in dairy fermented foods,
the microorganisms involved in the fermentation process belong to the lactic acid group of bacteria
(LAB). An alternative approach to making some of the health benefits that have been attributed
to fermented foods available is through the production of ‘fermentates’. The term ‘fermentate’
generally relates to a powdered preparation, derived from a fermented product and which can
contain the fermenting microorganisms, components of these microorganisms, culture supernatants,
fermented substrates, and a range of metabolites and bioactive components with potential health
benefits. Here, we provide a brief overview of a selection of in vitro and in vivo studies and patents
exclusively reporting the health benefits of LAB ‘fermentates’. Typically, in such studies, the potential
health benefits have been attributed to the bioactive metabolites present in the crude fermentates
and/or culture supernatants rather than the direct effects of the LAB strain(s) involved.
Keywords: fermentates; lactic acid bacteria (LAB); health effects; gut; immunomodulation; antimicrobial
1. Introduction
Several studies have reported the health benefits of fermented foods. Fermented foods typically
contain microorganisms of a generally regarded as safe (GRAS) status that can produce a number of
beneficial by-products/metabolites such as antimicrobial peptides (e.g., bacteriocins), ethanol, organic
acids, fatty acids, carbon dioxide, amongst others [1,2]. Fermentations typically involve the utilization
of compounds in the raw substrate by microorganisms, such as lactic acid bacteria (LAB) and yeasts [1].
The Lactic acid bacteria (LAB) are a group of bacteria that include genera such as Lactobacillus, Lactococcus,
Pediococcus, Enterococcus, and Streptococcus and are frequently found in dairy fermented foods [3]. Aside
from dairy fermented foods, LAB are also found in fermented vegetables [4,5], fermented meat [6,7],
and fermented cereals [8–10]. LAB-driven fermentations often yield by-products with bioactivity
and a diverse range of health-promoting effects, including protection against infectious agents,
immunomodulatory effects, anti-allergenic effects, anti-obesity effects, anti-oxidant effects, enhancing
the bioavailability of vitamins/minerals, anti-anxiety effects, among others [11–19]. For instance,
one meta-analysis has highlighted the effects of consuming LAB fermented foods and positive
impacts on weight maintenance [20], while separate studies have demonstrated that consumption
of fermented yogurts and dairy foods can attenuate the likelihood of developing cardiovascular
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disease (CVD) and type 2 diabetes mellitus (T2DM) [21–24]. Fermented milk has the potential to
ameliorate the mechanisms involved in glucose metabolism and reduce muscle pain associated with
resistance exercise [25], while other fermented foods such as kimchi have demonstrated anti-obesity
and anti-diabetic effects [26,27]. The mechanisms involved in insulin-mediated uptake of glucose can
be compromised in damaged muscles following exercise [28,29]. However, the above-mentioned study
by Iwasa et al. reported that fermented milk can result in an improvement in the ability of damaged
muscles to utilize glucose [25]. While there are limited clinical data in the area, studies have suggested
that fermented foods can have a positive impact on inflammatory bowel disease (IBD) symptoms [30].
Indeed, due to the LAB-associated fermented foods, the gut microbiota can also be altered in a positive
manner and such foods can thereby assist in the resolution of IBD [30,31]. It has been suggested
that fermented dairy products have the ability to positively modulate the gut microbiota, either by
stimulating the proliferation of beneficial microbes and/or by introducing novel species into the
gut [32–34]. Other investigators have studied the hypocholesteremic and anti-cancer properties of
these LAB-associated fermented as well as non-fermented milks [35]. Finally, several recent studies
have indicated that the consumption of fermented foods can be associated with improvements in mood
and cognitive function [36–38].
As mentioned, a range of bioactive compounds can potentially be produced during LAB
fermentation processes. One example of such bioactive components includes angiotensin converting
enzyme (ACE)-inhibitory peptides. More specifically, certain peptides associated with fermented
milks, such as valyl-prolyl-proline (VPP) and isoleucyl-prolyl-proline (IPP), display anti-hypertensive
characteristics and could potentially be harnessed as alternative/adjunct therapeutic options to
manage hypertension [39–43]. Some LAB strains can also produce exopolysaccharides (EPS)
during fermentation [44] and such EPS have shown anti-diabetic, cholesterol-reducing, anti-oxidant,
and immunomodulatory effects in a number of studies [45–48]. The cholesterol-lowering properties of
these EPS from LAB are likely to be elicited by decreasing cholesterol absorption in the gut, stimulating
the release of bile acids and by binding cholesterol [45,49,50]. Aside from their cholesterol-lowering
properties, EPS are also critical in host–microbe interactions by assisting the microbes to colonize
in the gut, as well as exerting immunomodulatory effects [51,52]. Several of these LAB strains can
also produce enzymes, such as amylase, protease, lipase, and glucoamylase, during fermentation
and thus assist in breaking down complex inedible substrates, thereby facilitating increased nutrient
absorption [53–55]. Other gut-associated benefits of LAB-derived fermented foods include an enhanced
capacity to absorb minerals due to the breakdown of phytic acid, addressing lactose intolerance,
inhibition of antibiotic-associated diarrhea (AAD), amongst other benefits. In vitro assays have
also indicated that fermented food-associated bioactives can exert anti-tumor effects on the gastric
cancer cell line, SGC7901 [56]. Finally, antimicrobial end-products such as bacteriocins (ribosomally
synthesized peptides) can also be produced during the fermentation process [57]. For more information
regarding the health benefits of fermented foods, the reader is referred to comprehensive reviews
by Marco et al. [1] and Macori et al. [2].
While it has been established in several studies and summarized in numerous reviews that
consumption of fermented foods and their associated microorganisms confers health benefits on the
host, for the purposes of this mini-review, we specifically focus on any such patents and studies
conducted with LAB ‘fermentates.’ When mentioning the term ‘fermentates’ hereafter, we refer to
compositions/formulations which are typically composed of LAB cells either in an active or inactive
state, along with the culture supernatants and fermentation media, which may contain metabolites and
bioactive components, which are often responsible for conferring the health benefits mentioned herein.
Any such fermentates typically undergo freeze-drying or spray-drying processes. Some potential
benefits of using fermentates include an extended shelf life, the possibility to use non-replicating
bacterial cells, as well as using fermentates as food ingredients, whilst simultaneously harnessing the
specific health benefits of fermented foods. Here, we summarize the studies and patents specifically
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related to the health benefits of LAB ‘fermentates.’ One key focus of the review is to determine to what
extent the health attributes associated with fermented foods can be found in fermentates.
2. Studies and Patents Relating to LAB Fermentates and Effects on Overall Health
2.1. LAB Fermentates and Gut Health
Thus far, there have been a very limited number of studies conducted specifically investigating the
effects of LAB fermentates on gut health. Nonetheless, in one relatively recent patent, Fasano and Budelli
reported the effects of fermentates produced with the LAB strain Lactobacillus paracasei CBA L74 (LMG
P-24778) with respect to alleviating gluten-associated disorders, such as gluten sensitivity and celiac
disease (Patent application number 18157990.5)(Patent number EP 3 351 554 A1) [58]. The inventors of
the patent noted that compositions containing the strain itself, the cell-free supernatants, fermentates
or metabolites of the culture somehow block or hinder gluten or gluten-associated polypeptides from
traversing the intestinal mucosa. By doing so, the negative effects of gluten and gluten-associated
peptides on patients with such disorders are somewhat mitigated. More specifically, the metabolites
associated with fermentates of this strain decreased the influx of gliadin peptides into human intestinal
epithelial cells. Undigested gliadin peptides typically trigger inappropriate innate as well as adaptive
T cell-mediated immune responses in the celiac small intestinal mucosa, leading to the symptoms
associated with gluten-associated diseases [59,60].
In addition to the above-mentioned effects, Fasano and Budelli found that the cell-free supernatants
of CBA L74 reduce the entry of dextran into cells [58]. The inventors postulate that the positive effects
exerted by fermentates derived from the CBA L74 strain can be ascribed to fermentation-derived
metabolites such as acetic acid, butyric acid, lactic acid, acetaldehyde, acetoin, diacetyl, butanediol,
ethanol, acetate, formate, either individually or in combination with each other, but there is limited
evidence provided to support this hypothesis or how these metabolites could reduce the uptake
of molecules. Although they were not fully characterized in the work described in the patent,
the metabolite(s) responsible for attenuating the entry of gliadin into cells is likely to be found in the
culture cell-free supernatants, culture media, or fermented media [58].
With regards to other studies relating to the effects of dairy fermented foods on gastrointestinal tract
(GIT) health and nutrient absorption, Saqib and co-workers [61] have shown that Propionibacterium spp.
can produce β-galactosidase (lactase), which breaks down lactose, thereby alleviating symptoms
associated with lactose intolerance [18,61,62]. Others have referred to the ability of Bifidobacterium
strains to assist in the digestion of lactose as well by producing lactic acid, thus resolving symptoms of
lactose intolerance [63]. Ultimately, the ability to break down lactose is a trait likely shared to some
extent by all LAB and bifidobacteria. Fermented foods encompassing Lactobacillus and Bifidobacterium
strains can contain a catalog of B vitamins as well [64–66]. Finally, a study by Rodríguez et al. has
highlighted the gastro-protective effects of LAB-derived fermented foods [67]. The study highlighted
the effectiveness of milks fermented with EPS-producing Streptococcus thermophilus strains CRL 804
and CRL 1190 in preventing chronic gastritis, using BALB/c mouse models. Administration of
milk fermented with strain CRL 1190 prevented the development of gastritis in mice which were
subsequently given acetylsalicylic acid, and resulted in gastric mucosa histology akin to healthy mice.
In addition, a significant increase in IL-10(+)-producing cells and a significant decrease in IFNgamma
(+)-producing cells were elicited by the fermented milk [67].
2.2. Effects of LAB Fermentates on Appetite Modulation and Weight Management
In relation to weight gain and modulation of appetite, studies conducted as part of the research
group, Food for Health Ireland (FHI), included the creation of a bank of a number of milk fermentates
using a range of LAB strains. Reconstituted skim milk (RSM) was utilized as a substrate for
fermentation since it is suitable for growing several LAB strains. As part of the study, several different
LAB strains belonging to the genera Lactobacillus, Lactococcus, Pediococcus, and Leuconostoc underwent
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the fermentation process in 10% as well as 30% RSM once their ability to grow in milk was established.
The conditions employed during fermentations were such that they were suitable for commercial scale
up. As expected, most of the LAB strains tested were able to grow during the fermentation process,
and this was confirmed by increases in cell numbers, with concomitant reductions in pH. A number
of in vitro assays were conducted with these LAB fermentates, including testing for the suppression
of pancreatic lipase (PL). PL is the main enzyme which hydrolyzes dietary fat into monoglycerides
and free fatty acids [68–70]. The various fermentates were screened for their ability to suppress PL,
with a view to decreasing fat absorption in the gut. It was shown that some of the fermentates were
able to reduce PL activity by up to 50%, compared to a 70% inhibition elicited by the commercial
medication Orlistat. The degree of PL inhibition varied with the particular species and strain of bacteria
used, as well as the fermentation conditions employed [71].
A major hormone, which is associated with suppression of appetite, is glucagon-like peptide-1
(GLP-1) and it has been suggested that induction of GLP-1 results in decreases in appetite and
consequent intake of food [72–74]. A study by Chaudhari and co-workers investigated the activity of
Lactobacillus helveticus NCDC 288 and NCDC 292-derived fermentates with respect to the expression
of cholecystokinin (CCK), proglucagon, and pro-gastric inhibitory peptide (pro-GIP) by real-time
polymerase chain reaction (PCR) [75]. The authors noted that the Lb. helveticus fermentates stimulated
the expression of CCK, pro-GIP, proglucagon, and GLP-1 from STC-1 cells. More specifically, CCK,
proglucagon, and pro-GIP gene expression was triggered by hydrolysates of whey protein and casein
protein, and this expression in turn stimulated the STC-1 cells (pGIP/Neo) to secrete GLP-1. However,
the authors were unable to recover one single active peptide from milk fermented with Lb. helveticus.
Nonetheless, this in vitro study showed that the fermentates from the Lb. helveticus strains used have
the ability to stimulate GLP-1 production and thus warrant further investigation in in vivo trials as
effective therapeutics for T2DM [75].
2.3. Immunomodulatory Effects of LAB Fermentates
Overall, there are a very limited number of studies conducted investigating LAB fermentates and
immunomodulation. Nonetheless, a patent outlining the immunomodulatory effects of fermentates
of the same Lb. paracasei CBA L74 strain mentioned previously was filed by Budelli and co-workers
(Patent application number 18166007.7) (Patent number EP 3 366 143 A1) [76]. In this patent,
the inventors outlined methods of obtaining the fermentates comprising the CBA L74 strain in
detail and reported the outcomes of various in vitro and in vivo assays conducted to evaluate the
immunomodulatory effects of such fermentates.
Aside from the methodology outlining the composition of the fermentates, the inventors
described the efficacy of Lb. paracasei CBA L74 fermented foods in modulating the mucosal immune
system. They demonstrated that exposure to CBA L74 cells induced increased production of the
anti-inflammatory cytokine IL-10 in in vitro assays involving co-culture of dendritic and Caco2 cells.
In animal studies, they demonstrated that administration of Lb. paracasei CBA L74 resulted in reduced
titers of the pro-inflammatory mediator IL-1β in the mucosa of mice. They also reported an up-regulation
and increase in production of Toll-like receptor 2 (TLR2) and TLR4, which are both critical players in the
immune system and are involved in the recognition of conserved microbial structures. Feeding skim
milk fermented with Lb. paracasei CBA L74 to mice resulted in a significant elevation of IL-10 in the
intestinal mucosa with only a modest increase in IL-1β titers; however, only minor changes in levels
of expression of TRL2 and TRL4 were observed. Thus, these data indicate that Lb. paracasei CBA
L74 and milk fermentates made using this strain can impact on the expression of different cytokines
and receptors involved in the innate immune system. Budelli et al. further hypothesize that foods
fermented with this CBA L74 strain may confer a health benefit via competitive exclusion of certain
pathogens, in addition to forming a protective barrier across the GIT mucosa. The Lb. paracasei CBA L74
cells can be in either an active or inactive form in the fermentate formulation [76]. Indeed, metabolites
present in the fermentates or culture supernatants, such as acetic acid, butyric acid, and lactic acid,
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synthesized by probiotics during fermentation, prior to heat inactivation, have also been reported
to confer health benefits on the host in other studies [77–81]. Thus, it may be the case that the
mucosal immune system can be upregulated upon exposure to fragments from the bacterial cell wall,
unmethylated CpG dinucleotides, and/or other proteins as well as lipids or carbohydrates associated
with the Lb. paracasei CBA L74 cells [76]. The CBA L74 strain can also be included in fermented foods,
and cell numbers in such fermented foods can vary between 1 × 102 colony forming units (cfu)/g
and 1 × 1012 cfu/g. The potential applications of such fermented foods include alleviating a wide
range of GIT disorders such as food allergies, bacterial or viral infections, Crohn’s disease, necrotizing
enterocolitis, amongst others [76].
2.4. In Vivo Studies Investigating the Anti-Infective Effects of LAB Fermentates
A few groups have investigated the anti-infective properties of LAB fermentates by conducting
in vivo studies. For instance, a patent filed by Fasano and Rescigno, utilizing the same Lb. paracasei
CBA L74 strain mentioned previously, described the effects of fermentates of the strain based on the
results of an animal trial (Patent application number 18209662.8)(Patent number EP 3 470 074 A1) [82].
The inventors described a decrease in the severity of an infection in offspring of lactating mice as
a result of the fermentate, and indicated that similar fermentates could potentially prove effective for
humans as well. Similar to other inventions, the optimum formulation consists of foods fermented by
this probiotic organism. The work outlined in the patent was conducted with pregnant or lactating
animals and it was determined that rice fermented with Lb. paracasei CBA L74 conferred a health benefit
when given to pregnant and lactating mice, in terms of attenuating the severity of infections caused by
Cronobacter sakazakii. Consumption of milk fermented with this strain by pregnant mice also resulted in
a protective effect against other pathogens such as Salmonella typhimurium FB62, Listeria monocytogenes,
and Escherichia coli. In order to tackle such infections in offspring of lactating mothers, the results of the
animal trial indicated that administration of the CBA L74-associated fermentate or fermented food to
lactating mothers is effective both prenatally, as well as postnatally [60,82].
A separate study conducted by Casey et al. reported the outcomes of an animal trial in which the
authors administered a mixture of five LAB strains as milk fermentates or milk suspensions to weaned
pigs for a period of 30 days [83]. These five LAB strains included Lactobacillus pentosus DPC6004,
Lactobacillus salivarius subsp. salivarius DPC6005, Pediococcus pentosaceus DPC6006, Lactobacillus murinis
DPC6002, and Lb. murinis DPC6003. After six days of administration of the LAB fermentates, the pigs
were infected with Salmonella serovar Typhimurium and the overall health and microbiological analysis
of their feces was conducted. The investigators determined that Salmonella numbers in feces were
significantly decreased and overall health of the animals improved as a consequence of administration
of the fermentates derived from the five LAB strains [83]. As part of the study, 10% RSM supplemented
with yeast extract was utilized to grow four of the five LAB strains, while RSM without yeast extract
was used to grow the remaining Lb. salivarius DPC6005 strain. The fermentates from the five LAB
strains were mixed together in order to feed the pigs for the trial which were fed a total of approximately
4 × 1010 cfu/day from the fermentates throughout the course of the trial. The authors also determined
that the cell numbers of each of the five strains contained in the mixed fermentate were approximately
equal to each other. Although not statistically significant, pigs fed with the LAB-derived fermentate
managed to gain more weight (mean increase of 632.4 ± 34.5 g/day) than the control group. The authors
also found that from the groups that were fed the LAB suspension or LAB fermentate, only 6/50 fecal
samples collected from the pigs post-Salmonella infection were positive for diarrhea. This compared
to 13/25 diarrhea-positive samples from the control treatment group. Average Salmonella numbers
present in feces from the LAB fermentate group were lower (2.04 log10 cfu/g feces), compared to
the control treatment group (3.51 log10 cfu/g), eight days post-infection. At 15 days post-infection,
the corresponding average Salmonella numbers for the fermentates treatment group of 1.42 log10
cfu/g feces, were significantly lower than the 3.68 log10 cfu/g for the control treatment group [83].
Finally, one study by Sreekumar and Hosono showed that skim milk medium fermentates containing
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Lb. acidophilus SBT2074 inhibited Escherichia coli 3544, and thus could have potential for individuals
with GIT infections with coliforms such as E. coli. [84].
A separate animal trial describing fermentates containing the bacteriocin, lacticin 3147,
was conducted with a view to treating bovine mastitis [85]. Lacticin 3147 is a relatively broad
spectrum two-component bacteriocin belonging to the lantibiotic subclass [86]. As part of the bovine
mastitis trial, Klostermann et al. developed a natural teat dip utilizing a fermentate encompassing
viable cells of Lactococcus lactis DPC3251, which produce lacticin 3147 [85]. Initial in vitro trials as part
of the study involved introducing 105 cfu/mL of the mastitis-causing pathogens, Streptococcus uberis
Diernhofer 1932AL, Streptococcus dysgalactiae subsp. dysgalactiae M, and Staphylococcus aureus DPC5246
into the lacticin 3147-containing fermentate. It was shown that Strep. dysgalactiae subsp. dysgalactiae
M and S. aureus DPC5246 were undetectable after 15 and 30 min respectively, whereas Strep. uberis
Diernhofer 1932AL numbers were decreased 100-fold after 15 min as a result of exposure to the
fermentate containing lacticin 3147. Following this, as part of the in vivo trials in the study, teats of
lactating dairy cows were coated with each of the pathogens and subsequently dipped into the teat
dips containing the lacticin fermentate. Strep. dysgalactiae was decreased by 97%, Strep. uberis by 90%,
and S. aureus by 80% after a 10 min dip contact time, thus demonstrating the efficacy of teat dips
containing lacticin fermentates [85].
In order to prepare the teat dip, the L. lactis DPC3251 strain was first grown in microbiological
media overnight and then subsequently in 10% RSM for 20 h at 30 ◦C [85]. This fermentate in RSM
was kept at 4 ◦C and utilized as the DPC3251 teat dip for the assays used in the study. In addition,
as a negative control, a fermentate from the bacteriocin-negative strain L. lactis DPC5399 was prepared
under the same conditions. The consistencies and pH of fermentates derived from both the DPC5321
and DPC5399 strains were very similar [85]. Furthermore, as part of the study, the authors evaluated
the stability of the DPC3251-derived fermentate when stored at 4 ◦C, with regards to maintenance
of bacteriocin antimicrobial activity. Encouragingly, the antimicrobial activity of the bacteriocin was
retained at 53% of its baseline level, even three weeks after storage of the fermentate at 4 ◦C [85].
2.5. In Vitro Studies Investigating the Effects of LAB Fermentates on Food-Borne Pathogens
A few studies have reported the antimicrobial effects of LAB fermentates on food-borne pathogens.
Examples of such cases include the development of whey powder-based spray-dried formulations
containing the bacteriocin lacticin 3147, produced by the LAB, L. lactis DPC3147 [86,87]. In the initial
study by Morgan and co-workers, which described the optimization of the formulation, the fermentate
containing lacticin 3147 was prepared by inoculating a 170 L volume of demineralized whey powder
(containing approximately 10% solids) with a 1% inoculum of L. lactis DPC3147, and fermentation
took place for 24 h with pH constant at 6.5 [87]. The fermentate was pasteurized at 72 ◦C for 15 s
prior to evaporation to 40% total solids. Finally, spray drying was employed to further concentrate
the fermentate and yield a powder containing bioactive lacticin 3147. After spray drying, the lacticin
3147-containing fermentate concentrated powder was evaluated for its ability to inhibit the pathogens
S. aureus 10 and L. monocytogenes Scott A in buffer at pH 5 and pH 7. Furthermore, the powder
was tested for its ability to target L. monocytogenes Scott A in infant milk formulations. Addition of
approximately 108 cfu of mid-exponential phase L. monocytogenes cells in 10% lacticin-enriched powder
led to an approximate 3-log decrease in viable cells within 3 h at 30 ◦C at both pH 5 and pH 7.
In contrast, the lacticin 3147-enriched powder was less effective at pH 5 against S. aureus 10, as addition
of approximately 107 cfu mid-exponential phase cells in a 15% solution of the lacticin powder merely
resulted in a log decrease within 3 h. However, there was a 3-log decrease at a neutral pH within 3 h.
Finally, a 99% decrease in L. monocytogenes numbers within 3 h was noted when tested in infant milk
formulations supplemented with the lacticin powder [87]. As part of a follow-up study, the authors
assessed the efficacy of this fermentate in targeting the food-borne pathogens Bacillus cereus and
L. monocytogenes. The fermentate elicited a 99.9% and 85% decrease in L. monocytogenes numbers within
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2 h in natural yogurt and cottage cheese respectively. Furthermore, B. cereus counts were decreased by
80% in soup within a 2 h timeframe in the presence of 1% lacticin 3147 powder [88].
With respect to other studies assessing fermentates derived from lantibiotic-producing LAB
strains, Field et al. compared the efficacies of nisin A and nisin V fermentates independently and
in combination with essential oils with a view to targeting L. monocytogenes [89]. Nisin A is a single
peptide lantibiotic and is used worldwide as a food preservative [90]. Nisin V is a bioengineered
derivative (with a methionine to valine substitution at residue 21) of the parental nisin A peptide,
and has demonstrated increased potency against a number of target strains [89]. Field and co-workers
found that the nisin V-containing fermentate, when combined with cinnamaldehyde and carvacrol,
was particularly effective at targeting L. monocytogenes. Importantly also, it was established that the
increased potency and specific activity of nisin V compared to nisin A was maintained in fermentate
form in growth media, as well as in food matrices [89].
Another bacteriocin which has been prepared in fermentate form includes pediocin PA-1. Pediocin
PA-1 is a class II bacteriocin, produced by the LAB, Pediococcus acidilactici, and is particularly potent
against L. monocytogenes [91–93]. Pediocin PA-1 can be prepared as a crude fermentate, an example of
which includes MicroGARD, and is commercially used as a food biopreservative and in particular
to reduce L. monocytogenes populations in food [94–96]. MicroGARD fermentates are available in
many forms from the company DuPont, including products ranging from MicroGARD 100, 200, 300,
400, 520, 730, CS1-50, CM1-50. There are slight variations in the benefits and applications of these
different products. For instance, MicroGARD 300, 400, 520, 730, CS1-50, and CM1-50 have the ability to
target Gram-positive bacteria, whereas MicroGARD 100, 200, 400, and 730 are effective at inhibiting
Gram-negative bacteria (DuPont). These MicroGARD fermentates can be utilized in a range of dairy
and non-dairy food products including yogurts, cottage cheese, pasta, sauces, baked products, cooked
meats, and soups. Pediocin PA-1 is also commercially marketed as a fermentate in the form of ALTATM
2431 by Kerry Group PLC and is chiefly utilized with a view to targeting food-borne pathogens in
ready to eat meat products [97]. This commercial fermentate maintains its stability and bioactivity
over a range of pH conditions and thus can be utilized to extend the shelf life of a wide range of dairy
products as well as other types of foods. Since the pediocin PA-1 producing strain is of GRAS status,
addition of fermentates containing this bacteriocin does not require extensive labelling [98].
Danisco has licenced several food-grade cultures and associated defined and undefined fermentates
which contain antimicrobial end products to control pathogens in food. Such cultures and undefined
fermentates are viewed as more consumer friendly and thus do not require extensive labelling, in contrast
to purified fermentates, which require extensive labelling as additives [89,99]. The HOLDBACTM
variety of cultures marketed by Danisco can potentially be applied in meat and dairy products to inhibit
the growth of bacterial and fungal pathogens. Other examples include Micocin, marketed by CanBiocin,
and this product exhibits antimicrobial activity against Listeria in processed meat. Defined antimicrobials
such as nisin are marketed as Nisaplin, whereas the product Natamax, produced by fermentation
by Streptococcus natalensis demonstrates antifungal activity (DuPont). In order to prepare Nisaplin,
non-fat milk is initially fermented with a nisin-producing L. lactis strain. The fermentate is further
spray dried and concentrated and the final product is composed of nisin at 1 × 106 IU/g, 74.4% sodium
chloride, 23.8% denatured milk solids, and 1.7% moisture [87–89,99]. Overall, Nisaplin is a heat-stable
fermentate and is used as a food preservative in a variety of foods such as dairy, meat, bakery
products, and beverages, and targets Gram-positive spoilage organisms and pathogens (DuPont).
Finally, NovaGARD is another commercial formulation, containing a crude preparation of nisin,
produced by DuPont. NovaGARD includes a range of products such as CB1, NR100, NR250, LM100,
and 285. These fermentates have different spectra of activity. For instance, products NR100, NR250,
and LM100 chiefly target Listeria in foods such as cooked and cured meats, fresh soups, and sauces.
On the other hand, product CB1 targets Gram-positive pathogens including Listeria, while NovaGARD
285 targets Gram-negative organisms and can be used to prolong the shelf life of refrigerated meals,
baked goods, soups, and sauces (DuPont).
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2.6. LAB Fermentates as ACE Inhibitors and Antioxidants
Overall, there has been a dearth of studies evaluating the blood pressure-lowering properties
of LAB-derived fermentates. In one such study however, Hayes and co-workers utilized
a Lb. animalis DPC6134 (NCIMB 41355) strain, which demonstrates proteolytic activity, to generate
a bovine sodium caseinate fermentate with a view to assessing the fermentate’s ACE inhibitory
activity [100]. Encouragingly, the 10 kDa DPC6134-associated fermentate showed an 85.51% (±15%)
ACE-inhibitory activity. In comparison to captopril, which demonstrated an inhibitory concentration
(IC50) value of 0.005 mg/mL, the DPC6134-associated fermentate demonstrated a 0.8 mg/mL IC50
value. Using a combination of membrane filtration and reverse-phase high performance liquid
chromatography (RP-HPLC), the authors were able to generate three bioactive fractions. These three
bioactive fractions (fractions 10, 19, and 43) demonstrated ACE-inhibitory percentage averages of 67.53,
83.71, and 42.36% respectively. Finally, by employing simulated gastrointestinal digestion conditions,
it was shown that the ACE-inhibitory 10 kDa DPC6134 fermentate was recalcitrant to a mix of digestive
enzymes including pepsin and corolase PP in the GIT [100].
Fuglsang et al. conducted an in vivo trial investigating the effects of fermentates from up to 26
different LAB strains on ACE inhibition [101]. The study demonstrated that the various synthesized
inhibitory substances demonstrated ACE-inhibitory activity in varying concentrations. On the basis of
spectrophotometric assays, the authors showed that there was a correlation between peptide formation
and ACE-inhibitory ability. Normotensive rats were utilized to ascertain the ACE-inhibitory activity
of any such active fermentates. Interestingly, pre-feeding the mice with Lb. helveticus fermented
milk reduced the pressor effects of angiotensin I (0.3 µg/kg), while one of the fermented milks
elicited an elevated response to bradykinin (10 µg/kg) in the normotensive rats. Thus, the authors
concluded that the Lb. helveticus strains synthesized ACE-inhibitory substances in vivo. While the
ACE-inhibitory effect elicited by the Lb. helveticus fermentates was relatively low compared to
commercial ACE-inhibitors, the fermented milk nonetheless attenuated the conversion of angiotensin
I to angiotensin II [101]. The enzyme ACE converts angiotensin I to angiotensin II, and angiotensin
II triggers vasoconstriction, and in turn, an increase in blood pressure. The reduced conversion
of angiotensin I to angiotensin II, elicited by the fermentates in the study by Fuglsang et al. [101],
may result in beneficial anti-hypertensive effects overall [102,103].
A separate study by Daliri et al. investigated the by-products of whey proteins fermented by up
to 34 LAB strains, with a particular focus on the ability of the fermentates to suppress ACE enzyme
activity [104]. Overall, it was demonstrated that the fermentates varied in their ability to suppress the
enzymes in vitro. There were seven promising fermentates which demonstrated potent ACE-inhibitory
activity in the range of 52.40%–84.7% and IC50 values ranging from 2.13–19.78 mg/mL. The strain which
possessed the most potent ACE-inhibitory activity was Pediococcus acidilactici SDL1414, with a value of
84.7% ACE-inhibition and IC50 value of 19.78 mg/mL. Interestingly, it was shown that up to 57.7% of
the peptides <7 kDa produced by this strain inhibited ACE. The strain SDL1414 may have potential as
a starter culture in the dairy industry with a view to being used to control hypertension [78,104].
In relation to the antioxidant activities associated with LAB-derived fermentates, Virtanen
and co-workers assessed the fermentates from several LAB strains grown in milk [105]. Out of
the 25 LAB strains evaluated in the study, fermentates from 6 strains demonstrated potent radical
scavenging ability, of which Lactobacillus jensenii ATCC 25258, Lb. acidophilus ATCC 4356, and Leuconstoc
mesenteroides subsp. cremoris-derived fermentates showed the highest level of antioxidant activity.
Overall, the lipid peroxidation inhibition activity of fermentates from these strains was weaker than the
radical scavenging ability. In four of these six strains, the radical scavenging activity was linked with
proteolytic activity. It was found that there was a correlation between potent radical scavenging ability
and a larger percentage of peptides ranging from 4–20 kDa found in the fermentates, and in general,
there was a higher proportion of hydrophobic amino acids present in these fermentates. Overall,
the antioxidative capabilities of the fermentates were strain specific and there was an association
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between the synthesis of radical scavengers and simultaneous proteolytic activity of the strains. On the
other hand, lipid peroxidation ability correlated with the degree of bacterial growth [105].
2.7. Effects of LAB Fermentates on Cognitive Health
In a recent study by Warda et al., the authors conducted a mouse trial and evaluated the impact of
feeding the mice a heat-killed fermentate composed of two Lactobacillus strains, with a particular focus
on impacts on host behavior and alterations in the host microbiota [106]. Encouragingly, mice which
were fed this fermentate (ADR-159), showed greater levels of sociability and had reduced baseline
corticosterone levels. The fermentate also resulted in minor alterations in the mouse microbiota and
impacted the less abundant taxa more dramatically than the dominant taxa. Furthermore, it was
encouraging that the fermentate did not elicit any undesired adverse effects on anthropometrics
and overall health of the mice [106]. ADR-159 was a co-fermentate of one Lactobacillus delbrueckii
and one Lactobacillus fermentum strain, along with the culture medium (which is composed of
lactose monohydrate, yeast extract, dipotassium phosphate, casein peptone, and sodium acetate).
The fermentate underwent extended high temperature treatment after production and there were
approximately 6 × 1010 viable bacterial cells present per gram of ADR-159 fermentate. ADR-159
was a commercial product synthesized by Adare Pharmaceuticals SAS. As part of the animal trial,
the final concentration of the ADR-159 fermentate incorporated into standard mice chow was 5%,
which resulted in approximately 3 × 109 cells per gram of chow [106].
A summary of patents and publications pertaining to the health benefits elicited by LAB fermentates
is included in Tables 1 and 2, respectively.
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Table 2. Publications relating to health benefits of LAB fermentates.
LAB Strains and
Associated Fermentates Effects Fermentation Substrate Reference
Lb. helveticus fermentates Stimulated GLP-1 production,anti-diabetic effect 11% RSM 75
Fermentates from a range of







and Lb. murinis DPC6003
Anti-Salmonella effect in pigs
All strains in 10% RSM with




Lb. acidophilus SBT2074 Inhibited Escherichia coli 3544 10% RSM 84
Fermentates of Lb. animalis
DPC6134 (NCIMB 41355) ACE inhibitory activity
2.5% sodium caseinate substrate
with 0.5% glucose 100
26 LAB fermentates ACE inhibitory activity 9.5% RSM 101
34 LAB fermentates. Most
potent was Pediococcus acidilactici
SDL1414
ACE inhibitory activity 20% Soybean protein isolates 104
Fermentates from Lactobacillus




Antioxidant activity Fresh pasteurized skim milk 105
Fermentates from Lb. delbrueckii










In this mini-review, we have summarized some key studies and patents relating to the diverse range
of health benefits conferred by LAB-derived fermentates. As mentioned, such fermentates can have
positive impacts on gut health, as well as overall general health. In many cases, the precise mechanisms
of action responsible for the health benefits exerted by these fermentates have not been elucidated,
and thus further in vitro, in vivo, and clinical trials are warranted to fully unravel such complex
mechanisms. Any such insights into the mode of action of such fermentates may reveal whether the
bacterial cells have to be active or whether the effects are merely mediated by cell surface components
and/or metabolites and bioactives present in the culture supernatants/fermentation media. Indeed,
the health benefits associated with biofunctional fermented foods can be exerted either by the live
microbes present in the foods themselves directly (probiotic effect) or via the metabolites and bioactive
products that the live microbes produce (bioactive effect) [11,107–109]. Furthermore, recent advances
in next generation sequencing technology can be harnessed to gain deeper insights into the impact that
LAB and fermentates thereof can have on the overall gut microbiota. Since there is a growing body of
evidence showing links between gut microbiota composition and overall health, the gut microbiota can
potentially be beneficially modulated by such LAB fermentates in a target-specific manner. Although
it is beyond the scope of this review, it must be noted that prebiotics represent another important
avenue with respect to beneficially modulating the gut microbiota. Indeed, a number of studies
and reviews have highlighted the ability of prebiotics such as inulin, fructo-oligosaccharides (FOS),
and galact-oligosaccharides (GOS) to modulate the gut microbiota, thereby leading to improvements
in gut health and overall health [110–118]. The primary focus of this review however has been about
the overall health benefits, including gut health benefits, derived from LAB fermentates.
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13. Drywień, M.; Frackiewicz, J.; Magdalena, G.; Gadek, J.; Jałosińska, M. Effect of probiotic and storage
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